The market keeps asking the wrong questions about
$TMDX.
Why did Waleed acquire Summit Aviation in 2023? Why accept margin compression at the exact moment the model was proving itself? Why enter cold storage with CHOPS after building the case against it for 26 years? Why deploy capital again into PAD Aviation in Europe?
These aren't contradictions. They're the same decision, made repeatedly.
Vertical integration of a service this complex is not a distraction from the moat, it is the moat. Every asset that looks like overhead from the outside is a coordination cost that a competitor would have to replicate before they could meaningfully compete. The margin compression is the price of making the network irreproducible.
What looks like poor capital allocation from a device-company framework looks very different when you understand that TransMedics stopped being a device company in 2022.
They are building the operating infrastructure of US organ transplantation. The NOP. The fleet. The routing algorithm. The digital ecosystem. The hub network. Each layer raises the cost of entry for anyone who comes after.
To understand why Summit was rational, why OCS commands a premium over cheaper alternatives, and why the current investment cycle is compressing margins intentionally, you need to understand the industry before the company.
That's what Part I of our deep dive covers: the 60-year failure of cold storage, the structural dysfunction of the OPO system, and how TransMedics was built from a one-man research project into the infrastructure behind 26% of all liver, heart, and lung transplants in the US.
Part II covers the numbers. CHOPS, next-gen lung and heart trials, OCS Kidney, full valuation. Coming soon.
Part I is live. Link in bio.